{"transactions":[{"id":4624058,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-09-18T20:59:23.000Z","date":"2026-09-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":165440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":39.21,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":165440},"source":{"system":"sec-edgar","filing":"0001772518-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000177251826000004/edgardoc.xml","form_type":"4"}},{"id":4624057,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-09-18T20:59:23.000Z","date":"2026-09-17","kind":"grant","planned":false,"acquired":true,"shares":165440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $7.18 per share, representing the fair market value per share of the Issuer's Common Stock on September 17, 2026 (the \"Repricing Date\"). Unless otherwise provided by the Issuer's board of directors or its compensation committee, if the option is exercised before the applicable retention period ends, the exercise price will revert to its original exercise price. The retention period begins on the Repricing Date and ends on the earliest of (i) the 18-month anniversary of the Repricing Date (March 17, 2028), (ii) a Sale Event (as defined in the Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan (the \"2025 Plan\")) or (iii) certain qualifying terminations of service."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":165440,"derivative":{"exercise_price":7.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":165440},"source":{"system":"sec-edgar","filing":"0001772518-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000177251826000004/edgardoc.xml","form_type":"4"}},{"id":4624056,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2026-09-18T20:59:23.000Z","date":"2026-09-17","kind":"grant","planned":false,"acquired":true,"shares":47268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest upon the achievement of a designated performance milestone, subject to the Reporting Person's continued service with the Issuer as of the vesting date."}],"balance_after":133069,"source":{"system":"sec-edgar","filing":"0001772518-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000177251826000004/edgardoc.xml","form_type":"4"}},{"id":4624055,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2026-09-18T20:59:23.000Z","date":"2026-09-17","kind":"grant","planned":false,"acquired":true,"shares":47269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest on June 17, 2027, subject to the Reporting Person's continued service with the Issuer as of the vesting date."}],"balance_after":85801,"source":{"system":"sec-edgar","filing":"0001772518-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000177251826000004/edgardoc.xml","form_type":"4"}},{"id":691787,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-08-10T23:00:13.000Z","date":"2026-08-06","kind":"grant","planned":false,"acquired":true,"shares":50740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in monthly increments over a period of three years from the grant date."}],"balance_after":50740,"derivative":{"exercise_price":14.54,"expiration_date":"2036-08-06","underlying":"Common Stock","underlying_shares":50740},"source":{"system":"sec-edgar","filing":"0001193805-26-001069","document":"e665686_4-ridloff.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526001069/e665686_4-ridloff.xml","form_type":"4"}},{"id":726440,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T22:00:05.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":6068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":6068,"derivative":{"exercise_price":99.87,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":6068},"source":{"system":"sec-edgar","filing":"0001193125-26-283138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526283138/ownership.xml","form_type":"4"}},{"id":784828,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-11T20:58:56.000Z","date":"2026-05-11","kind":"exercise","planned":true,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":13000,"derivative":{"exercise_price":31.2,"expiration_date":"2034-06-17","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001193125-26-217041","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526217041/ownership.xml","form_type":"4"}},{"id":784827,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T20:58:56.000Z","date":"2026-05-11","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":87,"value":261000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-217041","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526217041/ownership.xml","form_type":"4"}},{"id":784826,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T20:58:56.000Z","date":"2026-05-11","kind":"exercise","planned":true,"acquired":true,"shares":3000,"price":31.2,"value":93600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001193125-26-217041","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526217041/ownership.xml","form_type":"4"}},{"id":822966,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-01T23:00:03.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":14.18,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":4600},"source":{"system":"sec-edgar","filing":"0001193125-26-138372","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526138372/ownership.xml","form_type":"4"}},{"id":822965,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-01T23:00:03.000Z","date":"2026-03-31","kind":"exercise","planned":true,"acquired":false,"shares":7400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":4600,"derivative":{"exercise_price":14.18,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":7400},"source":{"system":"sec-edgar","filing":"0001193125-26-138372","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526138372/ownership.xml","form_type":"4"}},{"id":822964,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T23:00:03.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":1200,"price":86.05,"value":103260.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-138372","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526138372/ownership.xml","form_type":"4"}},{"id":822963,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T23:00:03.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":3400,"price":85.1946,"value":289661.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1200,"source":{"system":"sec-edgar","filing":"0001193125-26-138372","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526138372/ownership.xml","form_type":"4"}},{"id":822962,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T23:00:03.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":4600,"price":14.18,"value":65228.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."}],"balance_after":4600,"source":{"system":"sec-edgar","filing":"0001193125-26-138372","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526138372/ownership.xml","form_type":"4"}},{"id":822961,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T23:00:03.000Z","date":"2026-03-31","kind":"sale","planned":true,"acquired":false,"shares":7400,"price":85.3701,"value":631738.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.04 to $85.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-138372","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526138372/ownership.xml","form_type":"4"}},{"id":822960,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T23:00:03.000Z","date":"2026-03-31","kind":"exercise","planned":true,"acquired":true,"shares":7400,"price":14.18,"value":104932.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."}],"balance_after":7400,"source":{"system":"sec-edgar","filing":"0001193125-26-138372","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526138372/ownership.xml","form_type":"4"}},{"id":947322,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-01-06T21:11:05.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":165440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in forty-eight equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":165440,"derivative":{"exercise_price":39.21,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":165440},"source":{"system":"sec-edgar","filing":"0001772518-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000177251826000002/edgardoc.xml","form_type":"4"}},{"id":1050130,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock","published_at":"2025-09-03T21:16:21.000Z","date":"2025-09-02","kind":"sale","planned":true,"acquired":false,"shares":8836,"price":25.08,"value":221606.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":38532,"source":{"system":"sec-edgar","filing":"0002036042-25-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000203604225000053/edgardoc.xml","form_type":"4"}},{"id":1050129,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock","published_at":"2025-09-03T21:16:21.000Z","date":"2025-08-29","kind":"sale","planned":true,"acquired":false,"shares":748,"price":25.18,"value":18834.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":47368,"source":{"system":"sec-edgar","filing":"0002036042-25-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000203604225000053/edgardoc.xml","form_type":"4"}},{"id":1053794,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock","published_at":"2025-08-28T21:40:44.000Z","date":"2025-08-28","kind":"sale","planned":true,"acquired":false,"shares":16098,"price":25.97,"value":418065.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.01 to $26.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":48116,"source":{"system":"sec-edgar","filing":"0002036042-25-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000203604225000050/edgardoc.xml","form_type":"4"}},{"id":1053793,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock","published_at":"2025-08-28T21:40:44.000Z","date":"2025-08-27","kind":"sale","planned":true,"acquired":false,"shares":3618,"price":25.1,"value":90811.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":64214,"source":{"system":"sec-edgar","filing":"0002036042-25-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000203604225000050/edgardoc.xml","form_type":"4"}},{"id":1053792,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock","published_at":"2025-08-28T21:40:44.000Z","date":"2025-08-26","kind":"sale","planned":true,"acquired":false,"shares":3700,"price":25.13,"value":92981.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":67832,"source":{"system":"sec-edgar","filing":"0002036042-25-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000203604225000050/edgardoc.xml","form_type":"4"}},{"id":1059464,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock","published_at":"2025-08-21T20:04:52.000Z","date":"2025-08-20","kind":"sale","planned":true,"acquired":false,"shares":17500,"price":22.69,"value":397075.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.0000 to $23.355, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":71532,"source":{"system":"sec-edgar","filing":"0001482981-25-000143","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000148298125000143/edgardoc.xml","form_type":"4"}},{"id":1059463,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock","published_at":"2025-08-21T20:04:52.000Z","date":"2025-08-19","kind":"sale","planned":true,"acquired":false,"shares":34500,"price":21.08,"value":727260.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.6700 to $21.5700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":89032,"source":{"system":"sec-edgar","filing":"0001482981-25-000143","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000148298125000143/edgardoc.xml","form_type":"4"}},{"id":1101114,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T01:00:04.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":16000,"derivative":{"exercise_price":46.47,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-090579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025090579/ownership.xml","form_type":"4"}},{"id":1104562,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:35.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.95,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001415889-25-017835","document":"form4-06202025_040631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017835/form4-06202025_040631.xml","form_type":"4"}},{"id":1104561,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:35.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.48,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001415889-25-017835","document":"form4-06202025_040631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017835/form4-06202025_040631.xml","form_type":"4"}},{"id":1104560,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:35.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.53,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-25-017835","document":"form4-06202025_040631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017835/form4-06202025_040631.xml","form_type":"4"}},{"id":1104559,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:35.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":24.18,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":15450},"source":{"system":"sec-edgar","filing":"0001415889-25-017835","document":"form4-06202025_040631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017835/form4-06202025_040631.xml","form_type":"4"}},{"id":1104558,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:35.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26871,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":13.346,"expiration_date":"2030-09-10","underlying":"Common Stock","underlying_shares":26871},"source":{"system":"sec-edgar","filing":"0001415889-25-017835","document":"form4-06202025_040631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017835/form4-06202025_040631.xml","form_type":"4"}},{"id":1104557,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:35.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25879,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":13.346,"expiration_date":"2030-09-10","underlying":"Common Stock","underlying_shares":25879},"source":{"system":"sec-edgar","filing":"0001415889-25-017835","document":"form4-06202025_040631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017835/form4-06202025_040631.xml","form_type":"4"}},{"id":1104556,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T16:15:35.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":25296,"price":0.57,"value":14418.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-017835","document":"form4-06202025_040631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017835/form4-06202025_040631.xml","form_type":"4"}},{"id":1115108,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-11T20:47:50.000Z","date":"2025-06-11","kind":"exercise","planned":true,"acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following the vesting commencement date of June 29, 2022, subject to the reporting person's continued service relationship through each vesting date."}],"balance_after":4500,"derivative":{"exercise_price":20.29,"expiration_date":"2032-06-29","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0000950170-25-084893","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025084893/ownership.xml","form_type":"4"}},{"id":1115107,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T20:47:50.000Z","date":"2025-06-11","kind":"sale","planned":true,"acquired":false,"shares":4500,"price":50,"value":225000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-084893","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025084893/ownership.xml","form_type":"4"}},{"id":1115106,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T20:47:50.000Z","date":"2025-06-11","kind":"exercise","planned":true,"acquired":true,"shares":4500,"price":20.29,"value":91305.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person."}],"balance_after":4500,"source":{"system":"sec-edgar","filing":"0000950170-25-084893","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025084893/ownership.xml","form_type":"4"}},{"id":1125229,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-03T22:30:07.000Z","date":"2025-06-03","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":27.67,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000950170-25-081200","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025081200/ownership.xml","form_type":"4"}},{"id":1125228,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-03T22:30:07.000Z","date":"2025-06-03","kind":"sale","planned":true,"acquired":false,"shares":4800,"price":47,"value":225600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-081200","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025081200/ownership.xml","form_type":"4"}},{"id":1125227,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-03T22:30:07.000Z","date":"2025-06-03","kind":"sale","planned":true,"acquired":false,"shares":7200,"price":45.5,"value":327600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person."}],"balance_after":4800,"source":{"system":"sec-edgar","filing":"0000950170-25-081200","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025081200/ownership.xml","form_type":"4"}},{"id":1125226,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-03T22:30:07.000Z","date":"2025-06-03","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":27.67,"value":332040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 25, 2024 adopted by the reporting person."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0000950170-25-081200","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025081200/ownership.xml","form_type":"4"}},{"id":1276906,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-10T21:05:09.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":157820,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":157820,"derivative":{"exercise_price":18,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":157820},"source":{"system":"sec-edgar","filing":"0000950170-25-017032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000095017025017032/ownership.xml","form_type":"4"}},{"id":1468566,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-26T16:37:49.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":17000,"derivative":{"exercise_price":0.95,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001415889-24-018239","document":"form4-06262024_080646.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588924018239/form4-06262024_080646.xml","form_type":"4"}},{"id":1468565,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-26T16:37:49.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":11333,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25296,"source":{"system":"sec-edgar","filing":"0001415889-24-018239","document":"form4-06262024_080646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588924018239/form4-06262024_080646.xml","form_type":"4"}},{"id":1473318,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T21:00:11.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 18, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":16000,"derivative":{"exercise_price":31.2,"expiration_date":"2034-06-17","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-24-075711","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024075711/ownership.xml","form_type":"4"}},{"id":1843999,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:15:55.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":17000,"derivative":{"exercise_price":1.48,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-23-039696","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919123039696/doc4.xml","form_type":"4"}},{"id":1843998,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-26T16:15:55.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":11333,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13963,"source":{"system":"sec-edgar","filing":"0001209191-23-039696","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919123039696/doc4.xml","form_type":"4"}},{"id":1849733,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T20:15:26.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":12000,"derivative":{"exercise_price":27.67,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000899243-23-015968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924323015968/doc4.xml","form_type":"4"}},{"id":2217407,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-01T20:05:15.000Z","date":"2022-06-29","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years beginning on June 29, 2022."}],"balance_after":9000,"derivative":{"exercise_price":20.29,"expiration_date":"2032-06-28","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000899243-22-024748","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322024748/doc4.xml","form_type":"4"}},{"id":2219136,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T16:10:22.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":34000,"derivative":{"exercise_price":3.53,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-22-039779","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919122039779/doc4.xml","form_type":"4"}},{"id":2230126,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T20:05:54.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":12000,"derivative":{"exercise_price":14.18,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000899243-22-022792","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322022792/doc4.xml","form_type":"4"}},{"id":2296457,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-15T20:15:48.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":10459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":10459,"derivative":{"exercise_price":49.1,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":10459},"source":{"system":"sec-edgar","filing":"0000899243-22-014880","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322014880/doc4a.xml","form_type":"4/A","original_submission_date":"2021-06-17"}},{"id":2296527,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-15T20:15:21.000Z","date":"2021-03-12","kind":"grant","acquired":true,"shares":20919,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on March 12, 2021."}],"balance_after":20919,"derivative":{"exercise_price":56.1,"expiration_date":"2031-03-11","underlying":"Common Stock","underlying_shares":20919},"source":{"system":"sec-edgar","filing":"0000899243-22-014878","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322014878/doc4a.xml","form_type":"4/A","original_submission_date":"2021-03-16"}},{"id":2656692,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-23T21:20:06.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":15450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":15450,"derivative":{"exercise_price":24.18,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":15450},"source":{"system":"sec-edgar","filing":"0001209191-21-042888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121042888/doc4.xml","form_type":"4"}},{"id":2664100,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T20:49:40.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":20063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":20063,"derivative":{"exercise_price":49.1,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":20063},"source":{"system":"sec-edgar","filing":"0000899243-21-024443","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321024443/doc4.xml","form_type":"4"}},{"id":2734877,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Restricted Stock Units","published_at":"2021-04-30T22:55:12.000Z","date":"2021-04-29","kind":"exercise","acquired":false,"shares":3245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning 4/29/2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning 4/29/2020."}],"balance_after":6491,"derivative":{"underlying":"Common Stock","underlying_shares":3245},"source":{"system":"sec-edgar","filing":"0001209191-21-029359","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919121029359/doc4.xml","form_type":"4"}},{"id":2734876,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2021-04-30T22:55:12.000Z","date":"2021-04-30","kind":"sale","acquired":false,"shares":1032,"price":20.33,"value":20980.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":10553,"source":{"system":"sec-edgar","filing":"0001209191-21-029359","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919121029359/doc4.xml","form_type":"4"}},{"id":2734875,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2021-04-30T22:55:12.000Z","date":"2021-04-29","kind":"exercise","acquired":true,"shares":3245,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock."}],"balance_after":11585,"source":{"system":"sec-edgar","filing":"0001209191-21-029359","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919121029359/doc4.xml","form_type":"4"}},{"id":2786615,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-16T21:22:19.000Z","date":"2021-03-12","kind":"grant","acquired":true,"shares":40127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on March 12, 2021."}],"balance_after":40127,"derivative":{"exercise_price":56.1,"expiration_date":"2031-03-11","underlying":"Common Stock","underlying_shares":40127},"source":{"system":"sec-edgar","filing":"0000899243-21-011985","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321011985/doc4.xml","form_type":"4"}},{"id":2833464,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Restricted Stock Units","published_at":"2021-02-26T02:47:35.000Z","date":"2021-02-23","kind":"grant","acquired":true,"shares":9839,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning February 23 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning February 23 2022."}],"balance_after":9839,"derivative":{"underlying":"Common Stock","underlying_shares":9839},"source":{"system":"sec-edgar","filing":"0001209191-21-014559","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919121014559/doc4.xml","form_type":"4"}},{"id":2833463,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-02-26T02:47:35.000Z","date":"2021-02-23","kind":"grant","acquired":true,"shares":36231,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2022. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter."}],"balance_after":36231,"derivative":{"exercise_price":49.74,"expiration_date":"2031-02-23","underlying":"Common Stock","underlying_shares":36231},"source":{"system":"sec-edgar","filing":"0001209191-21-014559","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919121014559/doc4.xml","form_type":"4"}},{"id":2875062,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2021-02-09T02:00:27.000Z","date":"2021-02-04","kind":"sale","acquired":false,"shares":2051,"price":50.61,"value":103801.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":8340,"source":{"system":"sec-edgar","filing":"0001209191-21-008661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919121008661/doc4.xml","form_type":"4"}},{"id":2875061,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2021-02-09T02:00:27.000Z","date":"2021-02-04","kind":"grant","acquired":true,"shares":6490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 29, 2019, the reporting person was granted Restricted Stock Units (RSU's) that vest upon the Issuer's satisfaction of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the RSU's as to the number of shares reported in column 4 of row 1 above."}],"balance_after":10391,"source":{"system":"sec-edgar","filing":"0001209191-21-008661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919121008661/doc4.xml","form_type":"4"}},{"id":2912679,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Restricted Stock Units","published_at":"2021-01-09T00:29:34.000Z","date":"2021-01-06","kind":"exercise","acquired":false,"shares":1016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest in four equal annual installments beginning January 6, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest in four equal annual installments beginning January 6, 2021."}],"balance_after":9873,"derivative":{"underlying":"Common Stock","underlying_shares":1016},"source":{"system":"sec-edgar","filing":"0001209191-21-002832","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919121002832/doc4.xml","form_type":"4"}},{"id":2912678,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2021-01-09T00:29:34.000Z","date":"2021-01-06","kind":"sale","acquired":false,"shares":1016,"price":53.34,"value":54193.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":3901,"source":{"system":"sec-edgar","filing":"0001209191-21-002832","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919121002832/doc4.xml","form_type":"4"}},{"id":2912677,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2021-01-09T00:29:34.000Z","date":"2021-01-06","kind":"exercise","acquired":true,"shares":2722,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":4917,"source":{"system":"sec-edgar","filing":"0001209191-21-002832","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919121002832/doc4.xml","form_type":"4"}},{"id":3004820,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T15:52:52.000Z","date":"2020-10-14","kind":"purchase","acquired":true,"shares":2630,"price":19,"value":49970.0,"ownership":{"direct":true},"balance_after":2630,"source":{"system":"sec-edgar","filing":"0001209191-20-055043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919120055043/doc4.xml","form_type":"4"}},{"id":3165646,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Restricted Stock Units","published_at":"2020-05-01T22:00:12.000Z","date":"2020-04-29","kind":"exercise","acquired":false,"shares":3245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units vest in four equal annual installments beginning 4/29/2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units vest in four equal annual installments beginning 4/29/2020."}],"balance_after":9736,"derivative":{"underlying":"Common Stock","underlying_shares":3245},"source":{"system":"sec-edgar","filing":"0001209191-20-026615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120026615/doc4.xml","form_type":"4"}},{"id":3165645,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-01T22:00:12.000Z","date":"2020-04-29","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the 45,547 shares originally subject to the stock option vested and became exercisable on April 29, 2020, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":35547,"derivative":{"exercise_price":25.12,"expiration_date":"2029-04-29","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-026615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120026615/doc4.xml","form_type":"4"}},{"id":3165644,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2020-05-01T22:00:12.000Z","date":"2020-04-30","kind":"sale","acquired":false,"shares":1050,"price":49.22,"value":51681.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":2195,"source":{"system":"sec-edgar","filing":"0001209191-20-026615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120026615/doc4.xml","form_type":"4"}},{"id":3165643,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2020-05-01T22:00:12.000Z","date":"2020-04-29","kind":"exercise","acquired":true,"shares":3245,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock."}],"balance_after":3245,"source":{"system":"sec-edgar","filing":"0001209191-20-026615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120026615/doc4.xml","form_type":"4"}},{"id":3165642,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2020-05-01T22:00:12.000Z","date":"2020-04-29","kind":"sale","acquired":false,"shares":10000,"price":50.7353,"value":507353.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.50 to $51.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-026615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120026615/doc4.xml","form_type":"4"}},{"id":3165641,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2020-05-01T22:00:12.000Z","date":"2020-04-29","kind":"exercise","acquired":true,"shares":10000,"price":25.12,"value":251200.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-20-026615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120026615/doc4.xml","form_type":"4"}},{"id":3315480,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Restricted Stock Units","published_at":"2020-01-08T23:07:47.000Z","date":"2020-01-06","kind":"grant","acquired":true,"shares":10889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning January 6, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning January 6, 2021."}],"balance_after":10889,"derivative":{"underlying":"Common Stock","underlying_shares":10889},"source":{"system":"sec-edgar","filing":"0001209191-20-002602","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120002602/doc4.xml","form_type":"4"}},{"id":3315479,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-01-08T23:07:47.000Z","date":"2020-01-06","kind":"grant","acquired":true,"shares":39516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on January 6, 2021. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter."}],"balance_after":39516,"derivative":{"exercise_price":42.81,"expiration_date":"2030-01-06","underlying":"Common Stock","underlying_shares":39516},"source":{"system":"sec-edgar","filing":"0001209191-20-002602","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919120002602/doc4.xml","form_type":"4"}},{"id":3345667,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-11T23:29:36.000Z","date":"2019-12-09","kind":"exercise","acquired":false,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the 100,000 shares originally subject to the stock option vested and became exercisable on April 30, 2019, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":64000,"derivative":{"exercise_price":15.81,"expiration_date":"2028-04-29","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001209191-19-060100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919119060100/doc4.xml","form_type":"4"}},{"id":3345666,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2019-12-11T23:29:36.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":19478,"price":49.094,"value":956252.932,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.75 to $49.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-060100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919119060100/doc4.xml","form_type":"4"}},{"id":3345665,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2019-12-11T23:29:36.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":5502,"price":49.808,"value":274043.616,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.19 to $50.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":19478,"source":{"system":"sec-edgar","filing":"0001209191-19-060100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919119060100/doc4.xml","form_type":"4"}},{"id":3345664,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2019-12-11T23:29:36.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":11020,"price":50.595,"value":557556.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.17 to $51.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":24980,"source":{"system":"sec-edgar","filing":"0001209191-19-060100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919119060100/doc4.xml","form_type":"4"}},{"id":3345663,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2019-12-11T23:29:36.000Z","date":"2019-12-09","kind":"exercise","acquired":true,"shares":36000,"price":15.81,"value":569160.0,"ownership":{"direct":true},"balance_after":36000,"source":{"system":"sec-edgar","filing":"0001209191-19-060100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919119060100/doc4.xml","form_type":"4"}},{"id":3544599,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Restricted Stock Units","published_at":"2019-05-01T22:00:23.000Z","date":"2019-04-29","kind":"grant","acquired":true,"shares":12981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning April 29, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning April 29, 2020."}],"balance_after":12981,"derivative":{"underlying":"Common Stock","underlying_shares":12981},"source":{"system":"sec-edgar","filing":"0001209191-19-026846","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919119026846/doc4.xml","form_type":"4"}},{"id":3544598,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2019-05-01T22:00:23.000Z","date":"2019-04-29","kind":"grant","acquired":true,"shares":45547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on April 29, 2020. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter."}],"balance_after":45547,"derivative":{"exercise_price":25.12,"expiration_date":"2029-04-29","underlying":"Common Stock","underlying_shares":45547},"source":{"system":"sec-edgar","filing":"0001209191-19-026846","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919119026846/doc4.xml","form_type":"4"}},{"id":3569625,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Restricted Stock Units","published_at":"2019-04-02T20:30:52.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"75% of the shares subject to the Restricted Stock Units shall vest on the third anniversary of the grant date, and the remaining 25% shall vest on the fourth anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"75% of the shares subject to the Restricted Stock Units shall vest on the third anniversary of the grant date, and the remaining 25% shall vest on the fourth anniversary of the grant date."}],"balance_after":40000,"derivative":{"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-19-022500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000120919119022500/doc4.xml","form_type":"4"}}]}